edoc

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis

Joerger, Markus and Matter-Walstra, Klazien and Früh, Martin and Kühnel, Ursula and Szucs, Thomas D. and Pestalozzi, Bernhard and Schwenkglenks, Matthias. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Annals of oncology, 22 (3). pp. 567-574.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/64458/

Downloads: Statistics Overview

Abstract

Adding cetuximab to standard chemotherapy results in a moderate increase of overall survival in patients with advanced non-small-cell lung cancer (NSCLC), but the cost-effectiveness is unknown. Materials and methods: A Markov model was constructed based on the results of the First-Line ErbituX in lung cancer randomized trial, adding cetuximab to cisplatin-vinorelbine first-line chemotherapy in patients with advanced NSCLC. The primary outcome was the incremental cost-effectiveness ratio (ICER) of adding cetuximab, expressed as cost per quality-adjusted life year (QALY) gained, and relative to a willingness-to-pay threshold of ?60?000/QALY. The impact of cetuximab intermittent dosing schedules on the ICER was also evaluated.
Faculties and Departments:03 Faculty of Medicine > Departement Public Health > Pharmazeutische Medizin ECPM > Pharmazeutische Medizin (Szucs)
UniBasel Contributors:Matter-Walstra, Klazien Wietske and Schwenkglenks, Matthias
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Oxford University Press
ISSN:0923-7534
e-ISSN:1569-8041
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:12 Aug 2020 12:42
Deposited On:12 Aug 2020 12:42

Repository Staff Only: item control page